KIM, STANLEY A.,GIAMARELLOS-BOURBOULIS, EVANGELOS J.
申请号：
CA3053231
公开号：
CA3053231A1
申请日:
2018.02.16
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds interleukin-1a (IL-1a). Disclosed is the use of an antibody targeting and neutralizing interleukin 1 alpha (IL-1a), for the treatment of hidradenitis suppurativa (HS) in a human subject having lesions caused by the disease. More specifically, the use of the monoclonal antibody MABp1 is shown to be effective in reducing the number and/or size of inflammatory lesions in hidradenitis suppurativa.
